Molecular pathways and therapeutic targets in lung cancer

Emma Shtivelman _, Thomas Hensing, George R. Simon, Phillip A. Dennis, Gregory A. Otterson, Raphael Bueno and Ravi Salgia

PDF  |  HTML  |  How to cite

Oncotarget. 2014; 5:1392-1433. https://doi.org/10.18632/oncotarget.1891

Metrics: PDF 5710 views  |   HTML 15658 views  |   ?  


Emma Shtivelman1, Thomas Hensing2, George R. Simon3, Phillip A. Dennis4, Gregory A. Otterson5, Raphael Bueno6, Ravi Salgia7

1 Cancer Commons, Palo Alto, CA, United States of America

2 Northshore University Health System and University of Chicago, United States of America

3 MD Anderson Cancer Center, United States of America

4 Johns Hopkins University School of Medicine, United States of America

5 Ohio State University Comprehensive Cancer Center, United States of America

6 Brigham & Women’s Hospital, Harvard Medical School, United States of America

7 Department of Medicine, Section of Hematology/Oncology, University of Chicago, United States of America


Emma Shtivelman, email:

Keywords: lung cancer, targeted therapy, immune therapy

Received: March 18, 2014 Accepted: April 07, 2014 Published: April 08, 2014


Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1891